Condition: Multiple Myeloma · Sponsor: GlaxoSmithKline
This study is for adults with multiple myeloma (a type of blood cancer) that has come back after being treated earlier or isn't responding to the current treatment. The main goal is to find out if the study drug, belantamab mafodotin, given less often (on an extended schedule) with other cancer medicines, can still treat the cancer effectively while causing fewer side effects, especially those affecting the eyes. The study will also look at how well the treatment works overall and how safe it is when administered to the participants.
This description comes directly from the study's public registry record.
US GSK Clinical Trials Call Center · 877-379-3718 · GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center · +44 (0) 20 89904466 · GSKClinicalSupportHD@gsk.com
Always discuss trial participation with your own doctor first.
| GSK Investigational Site | Los Alamitos, California, United States | Recruiting |
| GSK Investigational Site | Torrance, California, United States | Recruiting |
| GSK Investigational Site | Whittier, California, United States | Recruiting |
| GSK Investigational Site | Fort Myers, Florida, United States | Recruiting |
| GSK Investigational Site | Macon, Georgia, United States | Recruiting |
| GSK Investigational Site | Baton Rouge, Louisiana, United States | Recruiting |
| GSK Investigational Site | Bethesda, Maryland, United States | Recruiting |
| GSK Investigational Site | Bridgeton, Missouri, United States | Recruiting |
| GSK Investigational Site | Springfield, Missouri, United States | Recruiting |
| GSK Investigational Site | Farmington, New Mexico, United States | Recruiting |
| GSK Investigational Site | Nashville, Tennessee, United States | Recruiting |
| GSK Investigational Site | Dunkirk, Nord, France | Recruiting |
+ 39 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07227311